An amputation alternative for patients with critical limb ischemia

International Journal of Angiology

Volumn 11, Issue 2, 2002, Pages 63-66

  Andreev, Andreia ^a,b   Petkov, Dimitar ^a   Kavrakov, Tanyo ^a  

^a TRAKIA UNIVERSITY   (Bulgaria)

^b NONE   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN E1;

ADULT; AGED; AMPUTATION; ARTICLE; ATHEROSCLEROSIS; BUERGER DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FLUSHING; HUMAN; HYPEREMIA; INJECTION SITE REACTION; LIMB ISCHEMIA; LIMB SALVAGE; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; RASH; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0036383135     PISSN: 10611711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00547-001-0059-3     Document Type: Article

References (36)

1. Andreev A, Lukanova D (1998) Non-operative treatment of the arterial diseases of the extremities. In: Vascular Diseases, Andreev A (ed). Academic Publishing House: Sofia, pp 285-290.
2. Balzer K, Rogatti W, Ruttgerodt K (1989) Efficacy and tolerability of intra-arterial and intravenous prostaglandin E1 infusions in occlusive arterial disease stage III / IV. VASA 28(suppl):31-38.
3. Bucci M, Iacobitti P, Laurora G, Cesarone MR (1998) Analysis of costs and results of prostaglandin (PGE1 alpha-cyclodestrin) therapy of peripheral arterial diseases. Minerva Cardioangiol 46, 10, 1(suppl):9-15.
4. Carlson LA, Eriksson I (1973) Femoral artery infusion of Prostaglandin E1 in severe peripheral vascular disease. Lancet 1:155-166.
5. Cohen LE, Faske I, Fenske NA, Greist MA (1989) Prostaglandin infusion therapy for intermittent digital ischemia in a patient with mixed connective tissue disease. Case report and review of the literature. J Am Acad Dermatol 20:893-897.
6. Creutzig A (1991) Therapy of peripheral arterial occlusive disease with special reference to prostaglandins. Z Gesamte Inn Med 46:59-67.
7. Diehm C, Her C, Stammler F (1988) Intravenose prostaglandin E1-therapie bei Patienten mit peripherer arterieller Verschlusskrankheit (AVK) in Stadium III: eine doppel-blinde, placebo-kontrollierte Studie. In: Prostaglandin E1-Virkungen und therapeutische Wir-samkheit, Heinrich H, Bohme H, Rogatti W (eds.). Springer-Verlag: Heidelberg, pp 133-143.
8. European Consensus Document on Critical Limb Ischaemia (1989) Recommendation 2A. Springer-Verlag: Berlin.
9. Gruss JD (1997) Effects of adjuvant PGE1 therapy following profundaplasty in patients with severe limb ischaemia. Early and long-term results. VASA 26:117-121.
10. Gruss JD, Bartels D, Haidar A, Vargas H, Simmenroth H (1983) Continuous intra-arterial perfusion of prostaglandin E1 in inoperable stage-IV arteriopathies. J Mal Vasc 8:133-137.
11. Gruss JD, Bartels D, Ohta T, Machado JL, Schlechtweg B (1982) Conservative treatment of inoperable arterial occlusions of the lower extremities with intra-arterial prostaglandin E1. Br J Surg 69(suppl):S11-S13.
12. Gruss JD, Vargas-Montano H, Bartels D, Simmenroth HW, Sakurai T, Schafer G, Fietze-Fisher B (1984) Use of Prostaglandins in Arterial Occlusive Diseases. Intern Angio 3(suppl):7-17.
13. Heidrich H, Dimroth H, Gutmann M, Helmis I, Peters A, Ranft J (1986) Longterm intravenous Infusion of PGE1. Peripheral Blood Flow disorders. In: Prostaglandin E1 in Atherosclerosis. Sinzinger H, Rogatti W (eds). Springer Verlag: Berlin, pp 92-98.
14. Heidrich H, Ranft J, Peters A, Rummel S (1987) Fruh - und Spatergebnisse nach intravenoser Prostavasin - therapie bei peripherarteriellen Durchblutungsstorungen mit Ruheschmerz und necrose. VASA 20(suppl):202-203.
15. Heidrich H, Penninger Ch, Preusen Av, Fahrig C (1999) PGE1 - Therapie beikritischer Extremitatenischamie mit tcPO2 - Werten von 0-20 mm Hg. VASA 54(suppl):27-29.
16. Hohlfeld T, Braun M (1997) Prostanglandin E1 Update on Effects and Efficacy (Scientific Forum). Cornelius Limbach GmbH: Köln, p 33
17. Lange E (1991) Current surgery/drug combination treatment of diabetic gangrene of the foot. Infection 19, 6(suppl):351-354.
18. Loosemore TM, Chalmers TC, Dormandy JA (1994) A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. Int Angiol 13:133-142.
19. Lukanova D, Batchvarova V, Petrov V (1997) Clinical assessement of the effect of Prostaglandin E1 in treatment of patients in III and IV stage of chronic arterial insufficiency of the extremities by Fontaine. 18th World Congress of the International Union of Angiology, Rome, Book of Abstracts.
20. Management of Peripheral Arterial Disease (PAD), In: TransAtlantic Inter-Society Consensus (TASC) (2000), Farmacotherapy for CLI. Inter Angio Vol, 1(suppl):212-215.
21. Management of Peripheral Arterial Disease (PAD), In: TransAtlantic Inter-Society Consensus (TASC) (2000), Definition and Nomenclature for CLI. Evaluation of CLI. Inter Angio Vol 1(suppl):183-198.
22. Occhionorelli S, Mascoli F, Vasquez G, Santini M, Navarra G, Carcoforo P, Donini I (1995) Use of PGE1 in severe ischemia of the lower extremities. Clinical study. Minerva Cardioangio 143:247-256.
23. Prostanoids for chronic critical leg ischaemia: a randomized, controlled, open-label trial with prostaglandin E1. The ICAI Study Group (1999) Ann Intern Med 130:412-421.
24. Rhodes RS, Heard SE (1993) Detrimental effect of high-dose prostaglandin E1 in the treatement of ischemic ulcers. Surgery 6:839-842.
25. Rudovski G, Peskar BA (1991) A comparison of different dosages of intraarterial and intravenous administred prostaglandin E1 in healthy volunteers. In: Prostaglandin E1. New Aspects of Pharmacology, Metabolism and Clinical Efficacy, Diehm C, Sinzinger H, Rogatti W (eds). Springer: Berlin, pp 58-71.
26. Sakaguchi S, Kusaba A, Mishima Y, Kamiya K, Nishimura A, Furukawa K, Shionoya S, Kawashima M, Katsumura T, Sakuma A (1978) A multi-clinical double blind study with PGE1 (α - cyclodextrin clathrate) in patients with ischemic ulcer of the extremities. VASA 7:263-266.
27. Sheffler P, de la Hamette D, Leipniz G (1991) Placebocontrolierte studie uber die Wirkung von i. v. PGE1 auf Makro- und Mikrozirkulation bei Patienten mit AVK Stadium III/IV. VASA 33(suppl):343-344.
28. Sheffler P, de la Hamette D, Leipniz G (1989) Therapeutic efficacy of intravenously applied Prostaglandin E1. VASA 18(suppl):19-25.
29. Sheffler P, de la Hamette D, Leipniz G, Gross G (1991) Effect of intravenous PGE1 on blood flow and microcirculation: a double blind, placebo-controlled study in patients with critical limb ischemia. In: Prostaglandin E1. New Aspects of Pharmacology, Metabolism and Clinical Efficacy. Diehm C, Sinzinger H, Rogatti W (eds). Springer: Berlin, pp 91-100.
30. Sheffler P, de la Hamette D, Rogatti W (1992) Prostaglandin E1 bei claudication intermitens. VASA 35(suppl):147-150.
31. Shionoya S (1984) Clinical experience with Prostaglandin E1 in occlusive arterial disease. Inter. Angio 3:99-103.
32. Shionoya S (1995) Buerger's disease (Thromboangiitis obliterans). In: Vascular surgery. 4th Edition, Rutherford R (ed). W.B. Saunders: Philadelphia pp 235-245.
33. Stricker H, Kaiser U, Frei J, Mahler F (1996) Acute and long-term effects of prostaglandin E1 assessed by clinical and microcirculatory parameters in critical limb ischemia: a pilot study. Int J Microcirc Clin Exp 16:57-63.
34. Trubestein G, Ludwig M, Diehm C, Gruss JD, Horsch S (1987) Prostaglandin E1 in stage III and IV arterial occlusive diseases results of a multicenter study. Dtsch Med Wochenschr 112:955-959.
35. Trubestein G, Ludwig M, Diehm C, Gruss JD, Horsch S (1983) Detrimental effect of high-dose prostaglandin E1 in the treatment of ischemic ulcers. Surgery 93:839-842.
36. Trubestein G, von Bary S, Breddin K, Diehm C, Gruss JD, Heinrich H, Horsch S (1989) Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease: a controlled randomised multicenter study. VASA 28(suppl):44-49.